BHVN vs. TGTX, LNTH, NUVL, TLX, AXSM, ADMA, AKRO, PCVX, RYTM, and KRYS
Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Biohaven vs. Its Competitors
Biohaven (NYSE:BHVN) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.
Biohaven presently has a consensus price target of $58.46, indicating a potential upside of 323.33%. TG Therapeutics has a consensus price target of $40.80, indicating a potential upside of 13.40%. Given Biohaven's stronger consensus rating and higher possible upside, equities analysts plainly believe Biohaven is more favorable than TG Therapeutics.
In the previous week, TG Therapeutics had 3 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for TG Therapeutics and 2 mentions for Biohaven. TG Therapeutics' average media sentiment score of 0.97 beat Biohaven's score of 0.31 indicating that TG Therapeutics is being referred to more favorably in the news media.
TG Therapeutics has a net margin of 10.13% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 18.88% beat Biohaven's return on equity.
Biohaven has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 14.6% of Biohaven shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
TG Therapeutics beats Biohaven on 10 of the 16 factors compared between the two stocks.
Get Biohaven News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biohaven Competitors List
Related Companies and Tools
This page (NYSE:BHVN) was last updated on 7/7/2025 by MarketBeat.com Staff
